Log in

NASDAQ:LGND - Ligand Pharmaceuticals Stock Price, Forecast & News

$88.54
-1.40 (-1.56 %)
(As of 01/24/2020 04:00 PM ET)
Today's Range
$87.85
Now: $88.54
$90.59
50-Day Range
$88.54
MA: $100.84
$109.08
52-Week Range
$84.45
Now: $88.54
$130.50
Volume342,473 shs
Average Volume328,506 shs
Market Capitalization$1.56 billion
P/E Ratio3.19
Dividend YieldN/A
Beta1.23
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:LGND
CUSIP53220K50
Phone858-550-7500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$251.45 million
Cash Flow$9.10 per share
Book Value$26.39 per share

Profitability

Net Income$143.32 million

Miscellaneous

Employees116
Market Cap$1.56 billion
Next Earnings Date2/6/2020 (Confirmed)
OptionableOptionable

Receive LGND News and Ratings via Email

Sign-up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter.


Ligand Pharmaceuticals (NASDAQ:LGND) Frequently Asked Questions

What is Ligand Pharmaceuticals' stock symbol?

Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."

How were Ligand Pharmaceuticals' earnings last quarter?

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) released its quarterly earnings results on Tuesday, November, 5th. The biotechnology company reported $0.49 EPS for the quarter, missing the consensus estimate of $0.61 by $0.12. The biotechnology company had revenue of $24.81 million for the quarter, compared to analyst estimates of $22.49 million. Ligand Pharmaceuticals had a return on equity of 7.47% and a net margin of 388.69%. The business's revenue was down 45.7% on a year-over-year basis. During the same period last year, the firm posted $1.32 earnings per share. View Ligand Pharmaceuticals' Earnings History.

When is Ligand Pharmaceuticals' next earnings date?

Ligand Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Ligand Pharmaceuticals.

How can I listen to Ligand Pharmaceuticals' earnings call?

Ligand Pharmaceuticals will be holding an earnings conference call on Thursday, February 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?

Ligand Pharmaceuticals issued an update on its FY19 earnings guidance on Tuesday, November, 5th. The company provided EPS guidance of ~$3.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.25. The company issued revenue guidance of ~$118 million, compared to the consensus revenue estimate of $119.01 million.

What price target have analysts set for LGND?

4 Wall Street analysts have issued twelve-month price targets for Ligand Pharmaceuticals' stock. Their forecasts range from $132.00 to $214.00. On average, they expect Ligand Pharmaceuticals' stock price to reach $166.50 in the next twelve months. This suggests a possible upside of 88.1% from the stock's current price. View Analyst Price Targets for Ligand Pharmaceuticals.

What is the consensus analysts' recommendation for Ligand Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ligand Pharmaceuticals.

What are Wall Street analysts saying about Ligand Pharmaceuticals stock?

Here are some recent quotes from research analysts about Ligand Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Ligand reported encouraging second-quarter results with earnings and sales beating estimates. The company’s Captisol Formulation technology resulted in partnerships with several leading drug companies like Novartis and Amgen that provide it with funds in the form of milestone and royalty payments. Ligand is acquiring other technology platforms like OmniAb platform from OMT acquisition to reduce dependence on Captisol formulation. OmniAb is likely to drive future revenues. However, Shares of Ligand have underperformed the industry so far this year. Moreover, Ligand derives a substantial portion of its revenues from royalties associated with the sales of Kyprolis. Any setback to Kyprolis will have an unfavorable impact on the top line. Moreover, increase in inactive licensing deals related to Ligand’s technology platform raises concerns." (8/8/2019)
  • 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $214 price target. Our target is based on sum of the parts including: (1) a clinical NPV model of assets in Phase 2 development or greater (currently 30 out of over 200 assets under development); and (2) NPV of current revenues based on our projections for royalties, material sales, and collaborative revenue." (5/3/2019)

Has Ligand Pharmaceuticals been receiving favorable news coverage?

Media headlines about LGND stock have been trending somewhat positive on Friday, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ligand Pharmaceuticals earned a news impact score of 1.2 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Ligand Pharmaceuticals.

Who are some of Ligand Pharmaceuticals' key competitors?

What other stocks do shareholders of Ligand Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Illumina (ILMN), Netflix (NFLX), Gilead Sciences (GILD), AbbVie (ABBV), Baidu (BIDU) and Intel (INTC).

Who are Ligand Pharmaceuticals' key executives?

Ligand Pharmaceuticals' management team includes the folowing people:
  • Mr. John L. Higgins, CEO & Exec. Director (Age 49)
  • Mr. Matthew W. Foehr, Pres & COO (Age 46)
  • Mr. Matthew Korenberg, Exec. VP of Fin. & CFO (Age 44)
  • Mr. Charles S. Berkman, Sr. VP, Gen. Counsel & Sec. (Age 50)
  • Mr. Todd Pettingill, Director of Corp. Devel.

Who are Ligand Pharmaceuticals' major shareholders?

Ligand Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Conestoga Capital Advisors LLC (3.53%), AMI Asset Management Corp (0.53%), Woodstock Corp (0.41%), Summit Creek Advisors LLC (0.40%), Falcon Point Capital LLC (0.05%) and State of Michigan Retirement System (0.03%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Stephen L Sabba, Sunil Patel and Todd C Davis. View Institutional Ownership Trends for Ligand Pharmaceuticals.

Which institutional investors are selling Ligand Pharmaceuticals stock?

LGND stock was sold by a variety of institutional investors in the last quarter, including Falcon Point Capital LLC, Conestoga Capital Advisors LLC, AMI Asset Management Corp, State of Alaska Department of Revenue, Louisiana State Employees Retirement System, Summit Creek Advisors LLC and State of Michigan Retirement System. View Insider Buying and Selling for Ligand Pharmaceuticals.

Which institutional investors are buying Ligand Pharmaceuticals stock?

LGND stock was purchased by a variety of institutional investors in the last quarter, including Woodstock Corp and Nisa Investment Advisors LLC. Company insiders that have bought Ligand Pharmaceuticals stock in the last two years include Jason Aryeh, John L Higgins and Sunil Patel. View Insider Buying and Selling for Ligand Pharmaceuticals.

How do I buy shares of Ligand Pharmaceuticals?

Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Ligand Pharmaceuticals' stock price today?

One share of LGND stock can currently be purchased for approximately $88.54.

How big of a company is Ligand Pharmaceuticals?

Ligand Pharmaceuticals has a market capitalization of $1.56 billion and generates $251.45 million in revenue each year. The biotechnology company earns $143.32 million in net income (profit) each year or $6.28 on an earnings per share basis. Ligand Pharmaceuticals employs 116 workers across the globe.View Additional Information About Ligand Pharmaceuticals.

What is Ligand Pharmaceuticals' official website?

The official website for Ligand Pharmaceuticals is http://www.ligand.com/.

How can I contact Ligand Pharmaceuticals?

Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected]


MarketBeat Community Rating for Ligand Pharmaceuticals (NASDAQ LGND)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  475 (Vote Outperform)
Underperform Votes:  344 (Vote Underperform)
Total Votes:  819
MarketBeat's community ratings are surveys of what our community members think about Ligand Pharmaceuticals and other stocks. Vote "Outperform" if you believe LGND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LGND will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel